CSI Market
Sign In | Register

Nls Pharmaceutics Ltd (NLSP) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access NLSP Annual Cash Flow →
The quarterly cash flow data below helps track how Nls Pharmaceutics Ltd's liquidity profile has evolved over recent quarters.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		0 0 0 (Dec 31 2024)
Operating Activities
Income-8.30
Depreciation & amortization0.06
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation0.77
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt0.00
Loss On Conversion Of Debt-
Financing Expenses Related To Convertible Instruments-
Theoretical Wages To An Interested Party-
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable, Related Parties0.00
Accounts Payable-0.58
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets0.20
Other Working Capital1.07
Other Noncash Income (Expense)0.00
Other net6.60
Payments for (Proceeds from) Other Operating Activities1.07
Discontinued operations0.00
Net Cash flow from Operating Activities-2.77
Investing Activities
Capital Expenditures0.01
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire Businesses, Net of Cash Acquired-1.71
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities1.70
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.29
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock2.34
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-14.42
Proceeds From Swiss Government Loan-
Proceeds From Bridge Loan-
Proceeds From Bridge Loans-
Payment On Swiss Government Loans-
Payment On Convertible Loans-
Payment On Convertible Loans Related Party-
Payment On Bridge Loan-
Proceeds From The Issuance Of Common Shares In A T M Financing-
Proceeds From The Issuance Of Prefunded Warrants Net-
Proceeds From Issuance Of Exercise Of Prefunded Warrants-
From Equity Issuance Costs-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents-
Debt Conversion Converted Instrument Amount-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities2.63
Effect of exchange rate on cash flow-0.01
Discontinued operations0.00
Free Cash Flow-2.76
Total Cash Flow1.55
4 historic quarters locked

Sign in to unlock the full Nls Pharmaceutics Ltd cash flow history.

Sign In Create Free Account

About Newcelx Ltd Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 20-F filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001213900-26-049307

Figures are derived from filed reports and may be restated. Historical data is subject to revision.